Mifegyne

Mifepristone, the active ingredient in Mifegyne, is a progesterone receptor antagonist presented as a 200 mg tablet for oral use. It treats medical termination of intrauterine pregnancy up to 49 days gestation and is also used off‑label for Cushing's syndrome.

GNH USA supplies Mifegyne as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mifepristone is a progesterone receptor antagonist used in specific reproductive and endocrine indications.

- Medical termination of intrauterine pregnancy (up to 49 days gestation): induces uterine lining breakdown and facilitates expulsion of the embryo. - Cushing's syndrome (off‑label): reduces cortisol production by blocking glucocorticoid receptors.

Mifepristone may cause a range of adverse reactions.

Common Side Effects: - Abdominal pain - Vaginal bleeding - Nausea - Diarrhoea - Fatigue - Headache

Serious or Rare Side Effects: - Heavy uterine bleeding requiring transfusion - Infection - Uterine rupture - Allergic reaction (anaphylaxis) - Elevated liver enzymes - Severe abdominal pain

Mifegyne should be used only under medical supervision with careful patient assessment.

- Confirm gestational age: ensure pregnancy is ≤49 days by ultrasound. - Medical supervision: administer under a qualified healthcare professional. - Contraindications: avoid in ectopic pregnancy, chronic adrenal failure, anticoagulant therapy. - Drug interactions: review concomitant medications, especially CYP3A4 inducers. - Pregnancy testing: verify pregnancy status before use. - Store at ambient temperature: keep below 25°C in original packaging, protect from moisture.

Mifegyne can interact with several drug classes; monitoring is essential.

Major Interactions (Avoid): - Rifampin (CYP3A4 inducer): may reduce efficacy of mifepristone. - Carbamazepine (CYP3A4 inducer): may lower drug levels. - Anticoagulants (e.g., warfarin): increased risk of bleeding when combined with misoprostol regimen.

Moderate Interactions (Monitor Closely): - Antifungal azoles (e.g., ketoconazole): may increase mifepristone exposure. - Antiretrovirals (e.g., efavirenz): may alter metabolism. - Hormonal contraceptives: may have reduced effectiveness during treatment.